Access to surgery where rheumatic heart disease is endemic a barrier to improving survival

Much of the mortality in rheumatic heart disease was attributable to heart failure, and was significantly reduced by interventional treatment, which may stand as a barrier to improving mortality in lower-income countries, data show.
An analysis of the large international Investigation of Rheumatic Atrial Fibrillation Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies (INVICTUS) program was published in JAMA.
“Rheumatic heart disease causes more than 300,000 deaths annually, mainly in low- and middle-income countries. In 2018, the member states of the World Health

Much of the mortality in rheumatic heart disease was attributable to heart failure, and was significantly reduced by interventional treatment, which may stand as a barrier to improving mortality in lower-income countries, data show.
An analysis of the large international Investigation of Rheumatic Atrial Fibrillation Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies (INVICTUS) program was published in JAMA.
“Rheumatic heart disease causes more than 300,000 deaths annually, mainly in low- and middle-income countries. In 2018, the member states of the World Health